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A B S T R A C T
We describe a patient with pulmonary cavitary pneumonia from whom we serially isolated
Mycobacterium kyorinense, an organism not previously reported in Australia, or associated with
cavitary disease. We discuss the clinical presentation, the isolation of the organism on several specimens
and initial management. M. kyorinense is a recently characterized species, which has previously only
been described in Japan and Brazil [1].
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Mycobacterium kyorinense is a non-pigmented slow growing
mycobacterium that was ﬁrst described in Japan. The species was
ﬁrst isolated in 2007 [1] and subsequently characterized as a novel
species in 2009 [2]. M. kyorinense is similar to Mycobacterium celatum
and Mycobacterium branderi however gene sequences of 16S rRNA,
hsp65 and rpoB differentiate it as a separate species [2]. To date, 12
patients with M. kyorinense infection have been described in the
literature; 11 in Japan and a single case in Brazil [1–5].
Previously described cases have been mostly immune-compe-
tent adults with predominantly pulmonary infections, although
single case reports describe lymph node and joint infections [4]. No
published cases have described cavitation as part of pulmonary
infection. Six of the 12 reported cases have died, with progressive
infection causing most of these deaths [3]. However all patients
who died received antimicrobials which likely were ineffective
against this organism, and their deaths preceded identiﬁcation of
this novel species as a human pathogen. Most patients who* Corresponding author at: Infectious Diseases Department, Western Health,
Footscray, Victoria 3011, Australia. Tel.: +61 412281269.
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4.0/).survived the infection received a combination of macrolide and
quinolone therapy [1].
The purpose of this article is to report the ﬁrst isolation of
M. kyorinense in Australia, and to the best of our knowledge the ﬁrst
report of pulmonary cavitation associated with this infection.
Case presentation
A 46-year-old Caucasian female was referred to our institution
in December 2012 following a CT-pulmonary angiogram per-
formed to investigate left sided pleuritic chest pain, which revealed
a large apical cavity with surrounding consolidation (Fig. 1). The
patient reported daily cough productive of brown sputum. There
was no associated dyspnoea, malaise or fatigue and no anorexia or
weight loss. The patient was Australian born and worked as a
computer programmer. Her only overseas travel was to Malta and
United Kingdom 30 years prior. She smokes cigarettes and had a
past history signiﬁcant for bilateral pleurodesis for recurrent
pneumothoraces as well as an anxiety disorder, for which she took
paroxetine. She did not report recurrent infections through
childhood or exposure to M. tuberculosis. A chest radiograph
6 years prior to presentation showed ‘ﬁbrocalciﬁc lesions in both
lung apices’.
Physical examination revealed a thin woman (BMI 19.6 kg/m2)
with normal vital signs. There was no clubbing or palpablee under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
Fig. 1. CT chest at presentation showing a left upper lobe cavity with areas of
consolidation and background changes of centrilobular emphysema.
Fig. 2. Expansion of the left upper lobe cavity and progression of the consolidation.
S. Muruganandan et al. / IDCases 2 (2015) 37–3938lymphadenopathy. Respiratory examination revealed coarse
breath sounds in the left upper zone upon auscultation. Examina-
tion was otherwise unremarkable.
Blood work revealed normal electrolytes, renal function and liver
function tests. Complete blood picture showed mild thrombocytosis
only. C-reactive protein and ESR were normal. Quantiferon-gold,
serum Aspergillus precipitins and HIV antibody were negative.
Serum immune-globulins revealed a mild increase in IgA (5.73 g/dL,
range 0.85–3.50), but were otherwise normal and alpha-1-
antitrypsin was normal. Pulmonary function testing revealed a
mild obstructive ventilatory defect and moderately reduced
diffusion capacity. The patient underwent a bronchoscopy, which
revealed inﬂammed left lingular segment airways with no
endobronchial lesions seen. Cytological analysis of the bronchial
specimens did not show any evidence of malignancy. A non-
tuberculous mycobacterium was isolated on culture of bronchial
washings, which subsequently identiﬁed as M. kyorinense.
Between 20 December 2012 and 7 November 2013, seven
pulmonary specimens were collected for analysis (two bronchos-
copy and ﬁve sputum). Small numbers of acid fast bacilli not
resembling M. tuberculosis were seen on direct smear from the ﬁrst
bronchial wash specimen. All specimens grew in Bactec MGIT 960
at an average of 13 days (range 7–30 days). MPT 64 TB antigen (BD
MGITTM TBc Identiﬁcation Test) testing was negative on the ﬁrst
isolate and all positive broth culture isolates were submitted to
Mycobacterial Reference Laboratory, Victorian Infectious Diseases
and Reference Laboratories for further testing (MRL, VIDRL). The
MRL identiﬁed the non-tuberculous mycobacterium as M. kyor-
inense by 16S ribosomal RNA gene sequencing. The MRL was
unable to perform sensitivity testing of the isolate.
Smoking cessation was encouraged however no anti-mycobac-
terial treatment was instituted initially due to uncertainty about the
signiﬁcance of the M. kyorinense isolate, and the patient’s symptoms
deteriorated over the following 3 months. Repeat CT chest showed
an increase in the size of the cavity as well as the development of
widespread tree-in bud opacities in the left and right upper lobes
(Fig. 2). A second bronchoscopy was performed which once again
yielded M. kyorinense. Clarithromycin, ethambutol and moxiﬂoxacinwere commenced empirically and consideration was given to
initiating an injectable aminoglycoside given the extensive cavita-
tion present [1].
Follow up after 7 months of therapy was completed although
the patient had continued to smoke and her adherence with
medication was uncertain. The patient continued to cough and M.
kyorinense was repeatedly isolated from the expectorated
sputum. Repeat CT imaging performed at 7 months showed
partial improvement of the lung inﬁltrates but persistence of
the cavity.
Discussion
We believe that our patient fulﬁls the proposed ATS/IDSA
criteria for non-tuberculous mycobacterial pulmonic infection, due
to M. kyorinense [6]. This is only the 13th reported case, the second
case outside Japan and the ﬁrst to report cavitation of the lung
parenchyma. This case adds to the emerging evidence that M.
kyorinense may be a pathogenic non-tuberculous mycobacterium
in humans, and, given this patient’s extended recent residence in
Australia, suggests the organism may have a wider geographical
distribution than previously described.
Since only 12 cases of pulmonary M. kyorinense disease have
previously been reported, it is difﬁcult to characterize speciﬁc
clinical ﬁndings of patients with this disease. It is not clear from
previously published cases of M. kyorinense infection whether
these patients were smokers, however at least three of the reported
cases have ‘COPD’ listed as a co-morbidity. Otherwise there
appears to be no other consistently reported co-morbid condition
predisposing to M. kyorinense infection [1]. Our patient had no
overt immune compromising conditions, however her history of
cigarette smoking, ﬁndings on her pulmonary function test as well
as her imaging ﬁndings support a diagnosis of GOLD stage 1 COPD
[9]. Additionally, her recurrent pneumothoraces and pleurodesis,
as well the historical reported apical changes on chest radiograph,
suggest possible structural lung disease. Indeed many other non-
tuberculous mycobacterial pulmonary infections occur in patients
with documented structural lung conditions or a history of
cigarette smoking [6].
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literature has revealed for most strains the MICs of rifampin,
ethambutol, and isoniazid were relatively high, and MICs of
macrolides, aminoglycosides, and quinolones were relatively low
[4]. Several patients subsequently determined to have M. kyorinense
infection appear to have received ﬁrst line M. tuberculosis therapy
empirically with little success [1]. Fluroquinolones in combination
with a macrolide seem to have been the most successful therapy
described [4]. Injectable aminoglycoside may also have a role in
management of M. kyorinense [1] and other non-tuberculous
mycobacteria [6–8]. Given the uncertainties regarding patient’s
adherence with medication, it is difﬁcult to assess treatment
response accurately, and whether the incomplete response after 6
months of therapy constitutes true treatment failure.
Conclusion
We describe the ﬁrst case of M. kyorinense pulmonary
infection in Australia, and the ﬁrst to be associated with
cavitary lung disease. This organism has gathering evidence for
its role as a pathogen in humans and further reports will inform
speciﬁc risk factors and therapies are appropriate for infections
it causes.
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